Tech Company Financing Transactions
Linnaeus Therapeutics Funding Round
Linnaeus Therapeutics secured a $12 million Series B funding round on 9/18/2019. Investors included Kairos Ventures and University of Pennsylvania.
Transaction Overview
Company Name
Announced On
9/18/2019
Transaction Type
Venture Equity
Amount
$12,000,000
Round
Series B
Investors
Kairos Ventures (Lead Investor)
Proceeds Purpose
The company intends to use the proceeds from the financing to conduct its phase 1/2 clinical trial of its lead compound, LNS8801, in patients with advanced cancer.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
30 Washington Ave. F
Haddonfield, NJ 08033
USA
Haddonfield, NJ 08033
USA
Phone
Website
Email Address
Overview
Linnaeus Therapeutics is a development stage biotech company engaged in the identification and development of small molecule agents for the treatment of cancer. Linnaeus is a Penn Center for Innovation UPstart company that was founded in 2016. Linnaeus is based upon discoveries from the Ridky lab at the University of Pennsylvania.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Patrick Mooney
Co-Founder
Todd Ridky
VP - R & D
Tina Garyantes
VP - R & D
Christopher Natale
Browse more venture capital transactions:
Prev: 9/18/2019: 120WaterAudit venture capital transaction
Next: 9/18/2019: Classcraft venture capital transaction
Share this article
About Database of VC Transactions
We do our best to record tech company VC transactions. All VC database entries on this site are derived from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs